Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/46068
Conference/Presentation Title: IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial.
Authors: Assouline S.;Kim W.S.;Sehn L.H.;Schuster S.J.;Cheah C.Y.;Nastoupil L.J.;Shadman M.;Yoon S.-S.;Matasar M.J.;Diefenbach C.;Gregory G.P.;Bartlett N.L.;Wei M.C.;Doral M.Y.;Yin S.;Negricea R.;Li C.-C.;Penuel E.;Huang H.;Budde L.E.
Institution: (Gregory) School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia
(Assouline) Jewish General Hospital, Montreal, QC, Canada
(Kim) Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
(Sehn) BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada
(Schuster) Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States
(Cheah) Linear Clinical Research and Sir Charles Gairdner Hospital, Nedlands, WA, Australia
(Nastoupil) MD Anderson Cancer Center, Houston, TX, United States
(Shadman) Fred Hutchinson Cancer Research Center, Seattle, WA, United States
(Yoon) Seoul National University Hospital, Seoul, South Korea
(Matasar) Memorial Sloan Kettering Cancer Center, New York, NY, United States
(Diefenbach) Perlmutter Cancer Center at NYU Langone Health, New York, NY, United States
(Bartlett) Washington University School of Medicine, St. Louis, MO, United States
(Wei, Doral, Yin, Li, Penuel) Genentech, Inc., South San Francisco, CA, United States
(Negricea, Huang) F. Hoffmann-La Roche Limited, Mississauga, ON, Canada
(Budde) City of Hope National Medical Center, Duarte, CA, United States
Presentation/Conference Date: 30-Aug-2021
Copyright year: 2021
Publisher: Elsevier Inc.
Publication information: Clinical Lymphoma, Myeloma and Leukemia. Conference: Society of Hematologic Oncology 2021 Annual Meeting. Hilton Americas, Houston United States. 21(Supplement 1) (pp S406-S407), 2021. Date of Publication: September 2021.
Abstract: Context: Follicular lymphoma (FL) often presents with recurrent relapses. Treatment options for patients (pts) with FL who have received >=2 prior lines of therapy are limited, and prognosis is poor. The safety and efficacy of mosunetuzumab, a full-length, fully humanized IgG1 CD20/CD3 bispecific antibody is currently being investigated in an ongoing open-label, multicenter, Phase I/Ib, dose-escalation and expansion trial in relapsed/refractory (R/R) B-cell lymphoma (GO29781; NCT02500407). Objective(s): To present updated data from the R/R FL cohort. Method(s): Pts received intravenous mosunetuzumab step-up doses in cycle (C) 1, days (D) 1 and 8, then the target dose on D15 and D1 of each subsequent 21-day cycle (Group B); treatment continued for <=17 cycles. Result(s): As of January 21, 2020, mosunetuzumab 0.4/1.0/2.8 mg to 1/2/13.5 mg (C1D1/8/15 dose levels) was given to 62 pts with FL who received >=2 prior systemic therapies. Pts had a median age of 59 (27-85) years, median number of 3 (2-11) prior therapies; 33 pts (53%) were double refractory, 30 (48%) had progression of disease within 24 months of first-line treatment (POD24), and four (6%) received prior chimeric antigen receptor T-cell (CAR-T) therapy. Overall response rate (ORR) and CR rate were 68% and 50%, respectively. In high-risk pts, consistent CR rates were observed: 55% (18/33) in pts with double refractory disease, 53% (16/30) in pts who had POD24, 78% (7/9) in pts with PI3Ki refractory FL, and 50% (2/4) in those who received prior CAR-T therapy. Twenty-six pts with a CR (74%) remained in remission (median time on study: 14.4 months). In responders (n=42), median duration of response was 20.4 months (95% CI: 11.7-not reached), and median progression-free survival was 11.8 months (95% CI: 7.3-21.9). Adverse events (AEs) and serious AEs were reported in 60 (97%) and 22 pts (35%), respectively. The most common grade (Gr) >=3 AEs included hypophosphatemia (23%) and neutropenia (21%). Fourteen pts (23%) experienced CRS1; events were mostly Gr 1 or 2, reversible, and occurred largely during C1. Conclusion(s): A high CR rate, durable responses, and a manageable safety profile were observed with mosunetuzumab monotherapy in heavily pre-treated pts with FL, including high-risk pts.Copyright © 2021 Elsevier Inc.
Conference Name: Society of Hematologic Oncology 2021 Annual Meeting
Conference Start Date: 20210-09-08
Conference End Date: 20210-9-11
Conference Location: Hilton Americas, Houston, United States
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/S2152-2650%2821%2901916-9
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/46068
Type: Conference Abstract
Subjects: cancer patient
cancer recurrence
cancer survival
chimeric antigen receptor T-cell immunotherapy
drug combination
drug safety
follicular lymphoma
high risk patient
hypophosphatemia
monotherapy
neutropenia
overall response rate
pharmacokinetics
progression free survival
remission
risk assessment
systemic therapy
bispecific antibody
CD20 antigen
CD3 antigen
endogenous compound
immunoglobulin G1
mosunetuzumab
Type of Clinical Study or Trial: Clinical trial
Appears in Collections:Conferences

Show full item record

Page view(s)

44
checked on Mar 15, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.